RARE Daily

Angion Discontinues Phase 2 Study of Kidney Disease Therapy Candidate

June 30, 2022

Angion Biomedica Corp. said it was discontinuing its JUNIPER phase 2 dose-finding trial of its experimental therapy ANG-3070, an oral tyrosine kinase inhibitor, in patients with primary proteinuric kidney diseases.

Photo: Jay Venkatesan, president and CEO of Angion

ANG-3070, is a highly selective, oral small molecule tyrosine kinase receptor inhibitor developed internally as a potential treatment for chronic fibrotic diseases, particularly in the kidney and lung. The study involved approximately 100 patients with primary proteinuric kidney diseases, including IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).

The decision followed a reassessment that found the occurrence of a potential safety signal of an unexpected and substantial decline in kidney function in a patient in the trial’s drug treatment arm and took into account a number of factors, including an evaluation of the totality of the data Angion has reviewed with respect to ANG-3070, known TKI class side effects, including potential adverse effects on the kidney, and an analysis of the blinded patient data which did not detect any early treatment signal indicating a reduction in proteinuria.

These factors collectively lead Angion to believe discontinuation of the JUNIPER study is in the best interest of patients. Angion is communicating with clinical trial sites and regulatory authorities regarding its decision to terminate the trial.

“Based on our ongoing analysis of the risk/benefit profile of ANG-3070 in patients with primary proteinuric kidney disease, we believe it to be in the best interest of patients to discontinue our phase 2 JUNIPER study at this time, notwithstanding the significant unmet need for new therapies in this patient population,” said Jay Venkatesan, president and CEO of Angion. “We are, of course, disappointed by today’s announcement and have made the decision to deprioritize the study of ANG-3070 in patients with established serious kidney disease. We will continue to evaluate the potential of ANG-3070 as a treatment for patients with idiopathic pulmonary fibrosis, as well as to consider all strategic and operational options for Angion and its pipeline going forward.”

Angion expects to report cash and cash equivalents of greater than $60 million at the end of the second quarter.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.